Davis Polk advised the joint book-running managers for a $50 million public offering of common stock by Ardelyx, Inc. The common stock is listed on the NASDAQ Global Market under the symbol “ARDX.”

Based in Fremont, California, Ardelyx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of minimally-systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat gastrointestinal and cardio-renal diseases.

The Davis Polk corporate team included partner Bruce K. Dallas, associates Jeffrey C. Lau and Dylan Service and summer law clerk Andrei Gribakov Jaffe. The tax team included partner Rachel D. Kleinberg and associate M. Brett Cameron. The intellectual property and technology team included partner Frank J. Azzopardi and associate Jason J. Bang. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post